S&P 500 7,500.58 ▲ 80.48 (+1.08%) DOW 51,564.70 ▲ 72.15 (+0.14%) NASDAQ 26,517.93 ▲ 496.28 (+1.91%) US Markets Closed â€ĸ 09:11 PM ET

CING

Cingulate Inc.

Price Chart
Latest Quote

$4.99

-0.13 (-2.54%)
Current Price
Previous Close $5.12
Open $5.13
Day High $5.23
Day Low $4.93
Volume 448,431
Fetched: 2026-06-19T22:39:39
Stock Information
Shares Outstanding 13.47M
Total Debt $7.43M
Cash Equivalents $25.89M
Net Income $-27.91M
Sector Healthcare
Industry Biotechnology
Market Cap $67.21M
EPS (TTM) $-4.33
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$44.46M
Income$-27.91M
Book/sh$1.58
Cash/sh$1.92
Employees14
Financial Ratios
Quick Ratio2.37
Current Ratio2.55
Debt/Eq39.38
Returns & Margins
ROA-69.68%
ROE-225.11%
Ownership
Insider Ownership30.54%
Institutional Ownership8.86%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-4.87
P/B3.15
Analyst Data
Recommendationstrong_buy
Target Price$23.31
Technical Indicators
SMA20$4.60
SMA50$4.95
SMA200$4.95
RSI60.98
ATR0.5702
Shares Float12.94M
Short Float20.95%
Short Ratio3.64
Volatility-0.85
Rel Volume0.59
Performance History
Week-1.96%
Month+13.67%
Quarter-33.56%
6 Months+28.94%
YTD+13.93%
Year+12.13%
3 Years-97.92%
10 Years-99.53%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-06-18 $4.99 506,500
2026-06-17 $5.12 720,600
2026-06-16 $4.74 632,100
2026-06-15 $4.93 247,100
2026-06-12 $4.88 179,300
2026-06-11 $5.09 294,400
2026-06-10 $4.89 315,900
2026-06-09 $4.65 423,000
2026-06-08 $4.53 207,700
2026-06-05 $4.49 364,400
2026-06-04 $4.80 611,000
2026-06-03 $4.88 1,125,600
2026-06-02 $4.03 4,511,300
2026-06-01 $3.60 2,189,400
2026-05-29 $4.16 1,040,600
2026-05-28 $4.34 775,400
2026-05-27 $3.96 1,413,000
2026-05-26 $4.78 863,000
2026-05-22 $4.47 480,700
2026-05-21 $4.74 296,400
2026-05-20 $4.63 247,800
2026-05-19 $4.39 229,900
About Cingulate Inc.

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Total Expenses $19,938,057 $15,645,265 $22,759,304 $17,502,280
Rent Expense Supplemental $327,000 $346,000 $496,000 $478,000
Other Income Expense $-1,150,673 $-1,013,868 - -
Net Non Operating Interest Income Expense $-1,361,130 $99,236 $-775,758 $-174,514
Total Other Finance Cost $1,361,130 $-99,236 $775,758 $174,514
Operating Expense $19,938,057 $15,645,265 $22,759,304 $17,502,280
General And Administrative Expense $10,164,000 $6,200,000 $7,266,000 $8,507,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-22,449,911 $-16,559,605 $-23,534,947 $-17,676,232
Net Interest Income $-1,361,130 $99,236 $-775,758 $-174,514
Normalized Income $-21,299,238 $-15,545,737 $-23,534,947 $-17,676,232
Net Income From Continuing And Discontinued Operation $-22,449,911 $-16,559,605 $-23,534,947 $-17,676,232
Total Operating Income As Reported $-19,938,108 $-15,644,973 $-22,759,189 $-17,501,718
Net Income Common Stockholders $-22,449,911 $-16,559,605 $-23,534,947 $-17,676,232
Net Income $-22,449,911 $-16,559,605 $-23,534,947 $-17,676,232
Net Income Including Noncontrolling Interests $-22,449,911 $-16,559,605 $-23,534,947 $-17,676,232
Net Income Continuous Operations $-22,449,911 $-16,559,605 $-23,534,947 $-17,676,232
Pretax Income $-22,449,911 $-16,559,605 $-23,534,947 $-17,676,232
Operating Income $-19,938,057 $-15,645,265 $-22,759,304 $-17,502,280
Per Share
Diluted EPS $-3.10 $-4.57 $-311.99 $-374.40
Basic EPS $-3.10 $-4.57 $-311.99 $-374.40
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-18,246,490 $-13,978,307 $-22,176,386 $-17,108,269
Total Unusual Items $-1,150,673 $-1,013,868 - -
Total Unusual Items Excluding Goodwill $-1,150,673 $-1,013,868 - -
Reconciled Depreciation $540,894 $653,090 $582,918 $394,011
EBITDA (Bullshit earnings) $-19,397,163 $-14,992,175 $-22,176,386 $-17,108,269
EBIT $-19,938,057 $-15,645,265 $-22,759,304 $-17,502,280
Diluted Average Shares $7,250,299 $3,402,306 $75,435 $47,212
Basic Average Shares $7,250,299 $3,402,306 $75,435 $47,212
Diluted NI Availto Com Stockholders $-22,449,911 $-16,559,605 $-23,534,947 $-17,676,232
Tax Provision $0 $0 $0 $0
Gain On Sale Of Security $-1,150,673 $-1,013,868 - -
Research And Development $9,774,057 $9,445,265 $15,493,304 $8,995,280
Selling General And Administration $10,164,000 $6,200,000 $7,266,000 $8,507,000
Other Gand A $6,104,000 $3,008,000 $2,583,000 $2,828,000
Insurance And Claims $741,000 $984,000 $1,543,000 $2,611,000
Rent And Landing Fees $327,000 $346,000 $496,000 $478,000
Salaries And Wages $2,992,000 $1,862,000 $2,644,000 $2,590,000
Fetched: 2026-06-19
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $2,508,907 $7,455,505 $-6,869,429 $3,882,022
Total Assets $15,073,263 $14,864,489 $3,491,436 $11,405,057
Total Non Current Assets $3,065,005 $2,203,686 $2,912,842 $3,535,405
Current Assets $12,008,258 $12,660,803 $578,594 $7,869,652
Other Current Assets $20,700 $54,865 $20,698 $20,698
Current Deferred Assets $59,383 $0 $178,780 $100,339
Prepaid Assets $966,779 $368,292 $312,078 $2,157,907
Receivables $8,013 $26,325 $14,622 $234,432
Other Receivables $8,013 $26,325 $14,622 $234,432
Cash Cash Equivalents And Short Term Investments $10,953,383 $12,211,321 $52,416 $5,356,276
Cash And Cash Equivalents $10,953,383 $12,211,321 $52,416 $5,356,276
Debt
Total Debt $8,786,555 $5,099,079 $3,510,241 $5,866,043
Long Term Debt And Capital Lease Obligation $2,251,731 $2,436,879 $135,099 $510,235
Long Term Debt $1,151,509 $2,436,879 - -
Current Debt And Capital Lease Obligation $6,534,824 $2,662,200 $3,375,142 $5,355,808
Current Debt $6,295,960 $2,527,108 $3,000,000 $5,000,000
Other Current Borrowings $6,295,960 $2,527,108 - -
Net Debt - - $2,947,584 -
Liabilities
Total Liabilities Net Minority Interest $12,564,356 $7,408,984 $10,360,865 $7,523,035
Total Non Current Liabilities Net Minority Interest $2,251,731 $2,436,879 $135,099 $510,235
Current Liabilities $10,312,625 $4,972,105 $10,225,766 $7,012,800
Payables And Accrued Expenses $3,322,624 $1,954,430 $6,257,602 $1,481,367
Interest Payable $563,883 $15,089 $290,000 $292,339
Payables $2,079,685 $1,470,280 $5,319,675 $819,219
Total Tax Payable $44,000 $200,000 $120,570 $56,862
Accounts Payable $2,035,685 $1,270,280 $5,199,105 $762,357
Current Notes Payable - $2,527,108 $3,000,000 $5,000,000
Other Current Liabilities - - - $339,755
Equity
Common Stock Equity $2,508,907 $7,455,505 $-6,869,429 $3,882,022
Total Equity Gross Minority Interest $2,508,907 $7,455,505 $-6,869,429 $3,882,022
Stockholders Equity $2,508,907 $7,455,505 $-6,869,429 $3,882,022
Gains Losses Not Affecting Retained Earnings $0 $0 - $0
Retained Earnings $-132,375,031 $-109,925,120 $-92,943,443 $-69,408,496
Other Equity Adjustments - - - -
Other
Ordinary Shares Number $7,250,299 $3,402,306 $97,293 $47,122
Share Issued $7,250,299 $3,402,306 $97,293 $47,122
Tangible Book Value $2,508,907 $7,455,505 $-6,869,429 $3,882,022
Invested Capital $9,956,376 $12,419,492 $-3,869,429 $8,882,022
Working Capital $1,695,633 $7,688,698 $-9,647,172 $856,852
Capital Lease Obligations $1,339,086 $135,092 $510,241 $866,043
Total Capitalization $3,660,416 $9,892,384 $-6,869,429 $3,882,022
Additional Paid In Capital $134,883,213 $117,380,285 $86,074,004 $73,290,457
Capital Stock $725 $340 $10 $61
Common Stock $725 $340 $10 $61
Preferred Stock $0 $0 $0 $0
Long Term Capital Lease Obligation $1,100,222 $0 $135,099 $510,235
Current Capital Lease Obligation $238,864 $135,092 $375,142 $355,808
Pensionand Other Post Retirement Benefit Plans Current $455,177 $355,475 $593,022 $175,625
Current Accrued Expenses $1,242,939 $484,150 $937,927 $662,148
Net PPE $3,065,005 $2,203,686 $2,912,842 $3,535,405
Accumulated Depreciation $-3,836,968 $-3,296,074 $-2,642,984 $-2,060,066
Gross PPE $6,901,973 $5,499,760 $5,555,826 $5,595,471
Leases $474,462 $474,462 $471,505 $471,505
Construction In Progress $233,397 $375,278 $207,976 $1,739,699
Other Properties $6,001,366 $4,457,272 $4,688,693 $3,196,615
Machinery Furniture Equipment $192,748 $192,748 $187,652 $187,652
Properties $0 $0 $0 $0
Other Short Term Investments - - - $0
Fetched: 2026-06-19
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-17,407,320 $-18,663,187 $-15,258,639 $-16,036,228
Operating Activities
Operating Cash Flow $-17,245,182 $-18,451,387 $-15,034,543 $-15,882,808
Cash Flow From Continuing Operating Activities $-17,245,182 $-18,451,387 $-15,034,543 $-15,882,808
Operating Gains Losses $1,956,624 $1,013,868 - -
Investing Activities
Capital Expenditure $-162,138 $-211,800 $-224,096 $-153,420
Investing Cash Flow $-162,138 $-211,800 $-224,096 $-152,652
Cash Flow From Continuing Investing Activities $-162,138 $-211,800 $-224,096 $-152,652
Net Other Investing Changes - - - $-165
Financing Activities
Issuance Of Capital Stock $10,153,812 $25,875,168 $6,970,826 $0
Financing Cash Flow $16,149,382 $30,822,092 $9,954,779 $4,898,991
Cash Flow From Continuing Financing Activities $16,149,382 $30,822,092 $9,954,779 $4,898,991
Net Common Stock Issuance $10,153,812 $25,875,168 $6,970,826 $0
Common Stock Issuance $10,153,812 $25,875,168 $6,970,826 $0
Net Other Financing Charges - - - $-85,919
Other
Repayment Of Debt $-4,430 $-17,063 $-16,047 $-15,090
Issuance Of Debt $6,000,000 $4,963,987 $3,000,000 $5,000,000
Interest Paid Supplemental Data $19,895 $6,288 $19,421 $19,000
End Cash Position $10,953,383 $12,211,321 $52,416 $5,356,276
Beginning Cash Position $12,211,321 $52,416 $5,356,276 $16,492,745
Changes In Cash $-1,257,938 $12,158,905 $-5,303,860 $-11,136,469
Net Issuance Payments Of Debt $5,995,570 $4,946,924 $2,983,953 $4,984,910
Net Long Term Debt Issuance $5,995,570 $4,946,924 $2,983,953 $4,984,910
Long Term Debt Payments $-4,430 $-17,063 $-16,047 $-15,090
Long Term Debt Issuance $6,000,000 $4,963,987 $3,000,000 $5,000,000
Net PPE Purchase And Sale $-162,138 $-211,800 $-224,096 $-153,420
Purchase Of PPE $-162,138 $-211,800 $-224,096 $-153,420
Change In Working Capital $830,852 $-4,554,224 $7,104,816 $598,617
Change In Other Current Liabilities $1,208,424 $-358,087 $-339,755 $-295,595
Change In Other Current Assets $-1,240,075 $267,886 $263,741 $227,982
Change In Payables And Accrued Expense $1,467,896 $-4,540,719 $5,193,632 $791,005
Change In Prepaid Assets $-623,705 $88,399 $1,767,388 $-580,591
Change In Receivables $18,312 $-11,703 $219,810 $455,816
Other Non Cash Items $352,531 - - -
Stock Based Compensation $1,523,828 $995,484 $812,670 $800,796
Depreciation Amortization Depletion $540,894 $653,090 $582,918 $394,011
Depreciation And Amortization $540,894 $653,090 $582,918 $394,011
Depreciation $540,894 $653,090 $582,918 $394,011
Gain Loss On Investment Securities $1,150,673 $1,013,868 - -
Net Income From Continuing Operations $-22,449,911 $-16,559,605 $-23,534,947 $-17,676,232
Net Short Term Debt Issuance - - $3,000,000 $0
Short Term Debt Issuance - - $3,000,000 $5,000,000
Net Investment Purchase And Sale - - $0 $933
Sale Of Investment - - $0 $933
Short Term Debt Payments - - - $0
Purchase Of Investment - - - -
Fetched: 2026-06-19